TY - JOUR
T1 - Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system
AU - Matsui, Toshiro
AU - Tamaya, Kei
AU - Seki, Eiji
AU - Osajima, Katsuhiro
AU - Matsumoto, Kiyoshi
AU - Kawasaki, Terukazu
PY - 2002
Y1 - 2002
N2 - 1. Intact absorption of the bioactive dipeptide Val-Tyr (VY), with in vivo antihypertensive ability in normotensive human subjects, was investigated. 2. As a result of a single oral administration of VY, the VY absorption curve occurred maximally over the second hour postprandially; a greater than 10-fold higher increment of VY following a dose of 12 mg was observed in the plasma at 2 h compared with the baseline concentration of VY at 0 h (1934 ± 145 vs 159 ± 11 fmol/mL plasma, respectively). 3. Plasma VY levels increased with dose administered (3, 6 and 12 mg), suggesting that exogenous VY could be absorbed intact into the human blood depending on the dose. The elimination half time (t1/2) of VY was estimated to be 3.1 h. The area under the curve for the 12 mg VY dose was 9185 ± 688 fmol·h/mL plasma.
AB - 1. Intact absorption of the bioactive dipeptide Val-Tyr (VY), with in vivo antihypertensive ability in normotensive human subjects, was investigated. 2. As a result of a single oral administration of VY, the VY absorption curve occurred maximally over the second hour postprandially; a greater than 10-fold higher increment of VY following a dose of 12 mg was observed in the plasma at 2 h compared with the baseline concentration of VY at 0 h (1934 ± 145 vs 159 ± 11 fmol/mL plasma, respectively). 3. Plasma VY levels increased with dose administered (3, 6 and 12 mg), suggesting that exogenous VY could be absorbed intact into the human blood depending on the dose. The elimination half time (t1/2) of VY was estimated to be 3.1 h. The area under the curve for the 12 mg VY dose was 9185 ± 688 fmol·h/mL plasma.
UR - http://www.scopus.com/inward/record.url?scp=0036126473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036126473&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1681.2002.03628.x
DO - 10.1046/j.1440-1681.2002.03628.x
M3 - Article
C2 - 11906484
AN - SCOPUS:0036126473
VL - 29
SP - 204
EP - 208
JO - Clinical and Experimental Pharmacology and Physiology
JF - Clinical and Experimental Pharmacology and Physiology
SN - 0305-1870
IS - 3
ER -